Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBIO" or "the Company") (NASDAQ: AVRO) for violations of the securities laws.
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 163,500 shares of the company’s common stock to five new employees as inducement awards, consisting of 30,500 shares granted under the company’s 2019 Inducement Plan and 133,000 shares granted under the company’s 2020 Inducement Plan. The gran...
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.
NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AVROBIO, Inc. ("AVROBIO" or "the Company") (NASDAQ:AVRO).
WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public.
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial. In March, the FDA granted full approval to Sanofi's SA (NASDAQ: SNY) Fabrazyme (agalsidase beta) after it received accelerated approval based on a surrogate endpoint of reduction of GL-3 inclusions in biopsied renal peritubular capillaries (PTCs). The conversion of Fabrazyme to full approval limits the accelerated approval path...